» Articles » PMID: 38833004

The VISTA/VSIG3/PSGL-1 Axis: Crosstalk Between Immune Effector Cells and Cancer Cells in Invasive Ductal Breast Carcinoma

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

A checkpoint protein called the V-domain Ig suppressor of T cell activation (VISTA) is important for controlling immune responses. Immune cells that interact with VISTA have molecules, or receptors, known as VISTA receptors. Immune system activity can be modified by the interaction between VISTA and its receptors. Since targeting VISTA or its receptors may be beneficial in certain conditions, VISTA has been studied in relation to immunotherapy for cancer and autoimmune illnesses. The purpose of this study was to examine the expression levels and interactions between VISTA and its receptors, VSIG3 and PSGL-1, in breast cancer tissues. IHC analysis revealed higher levels of proteins within the VISTA/VSIG3/PSGL-1 axis in cancer tissues than in the reference samples (mastopathies). VISTA was found in breast cancer cells and intratumoral immune cells, with membranous and cytoplasmic staining patterns. VISTA was also linked with pathological grade and VSIG3 and PSGL-1 levels. Furthermore, we discovered that the knockdown of one axis member boosted the expression of the other partners. This highlights the significance of VISTA/VSIG3/PSGL-1 in tumor stroma and microenvironment remodeling. Our findings indicate the importance of the VISTA/VSIG3/PSGL-1 axis in the molecular biology of cancer cells and the immune microenvironment.

Citing Articles

Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.

Franzese O Int J Mol Sci. 2024; 25(23).

PMID: 39684559 PMC: 11641238. DOI: 10.3390/ijms252312848.


VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study.

Shekari N, Shanehbandi D, Baghbani E, Safaei S, Masoumi J, Baradaran B Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39365310 DOI: 10.1007/s00210-024-03491-z.

References
1.
Xie X, Chen C, Chen W, Jiang J, Wang L, Li T . Structural Basis of VSIG3: The Ligand for VISTA. Front Immunol. 2021; 12:625808. PMC: 8027081. DOI: 10.3389/fimmu.2021.625808. View

2.
Yuan L, Tatineni J, Mahoney K, Freeman G . VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy. Trends Immunol. 2021; 42(3):209-227. PMC: 8088836. DOI: 10.1016/j.it.2020.12.008. View

3.
Digomann D, Strack J, Heiduk M, Plesca I, Rupp L, Reiche C . VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer. Cancers (Basel). 2023; 15(8). PMC: 10136841. DOI: 10.3390/cancers15082326. View

4.
Huang Y, Zheng D, Yang Q, Wu J, Tian H, Ji Z . Global trends in -related breast cancer research from 2013 to 2022: A scientometric analysis. Front Oncol. 2023; 13:1197168. PMC: 10354558. DOI: 10.3389/fonc.2023.1197168. View

5.
Holler A, Nguyen-Strauli B, Frauchiger-Heuer H, Ring A . "Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?". Breast Cancer (Dove Med Press). 2023; 15:525-540. PMC: 10392911. DOI: 10.2147/BCTT.S340741. View